A new Stanford study the first to show that the anti-malarial drug hydroxychloroquine (HCQ) may target the autoinflammatory component of CRPS.
A lupus cohort study from British Columbia, Canada has shown that medication adherence with hydroxychloroquine (HCQ) is associated with a 71% to 83% lower mortality.
No matter what opinions there are, the public ought to be treated like adults, allowed to to see it and decide for themselves.
In this study, SARS-CoV-2 infected non-hospitalized patients hydroxychloroquine exposure was associated with a decreased rate of subsequent hospitalization.
The US Food and Drug Administration on Monday revoked its emergency use authorization for hydroxychloroquine to treat Covid-19, but quickly came under fire from President Donald Trump, who said only US agencies have failed to grasp its benefit in fighting the coronavirus.
The study, which was obviously flawed on its face (I commented well before it was exposed that the groupings made no sense), turned out to be produced by a shell company, with unverified data gathered by non-scientists.
